secwatch.observer — SEC 8-K summary
======================================

Issuer:     WINDTREE THERAPEUTICS INC /DE/ (WINT)
CIK:        0000946486
Form:       8-K
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0001437749-23-009015
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Windtree reports FY2022 net loss $39.2M; cash runway into Q2 2023 only
----------------------------------------------------------------------

- Q4 2022 net loss $9.7M ($13.01/share); FY2022 net loss $39.2M ($62.23/share).
- Operating loss Q4 $10.8M includes $6.8M rostafuroxin impairment; FY operating loss $41.3M includes $12.6M goodwill impairment.
- Cash and equivalents $6.2M at Dec 31, 2022; expects to fund operations into Q2 2023 only.
- Raised $1.0M from warrant exercises; R&D expense fell to $1.2M in Q4 from $4.5M YoY.
- Istaroxime SEISMiC study met primary endpoint (p=0.017) in early cardiogenic shock; new patent for longer infusion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946486/000143774923009015/0001437749-23-009015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946486/000143774923009015/wint20221118b_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-009015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer